Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...

Researchers investigating the role of the protein CD44 in obesity and metabolic health found that CD44-deficient mice stayed ...

Pseudomonas aeruginosa is notorious for its role in food spoilage and infections, posing a significant threat to both food ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Physicians want to lessen chronic disease incidence. However, the approach of the Make America Healthy Again initiative ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Shareholders sued Allarity over alleged false statements about the prospects for approval of the firm's investigational kidney cancer therapy.

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO and a healthy cash position. See ...

Harnessing the Power of AI to Accelerate Cancer Drug Development ...

Scientists at the (UNIGE) have developed a tool that uses light to precisely control where and when a drug becomes active, ensuring it works exactly where it's needed. For medical treatments to be ...